Baird initiated coverage of Neurogene (NGNE) with an Outperform rating and $54 price target. The company’s lead agent NGN-401 is a gene therapy for Rett syndrome using its self-regulating Exact technology, the analyst tells investors in a research note. The firm views NGN-401 as promising due to its preclinical and early clinical data to date, and its selection by FDA for both Breakthrough Therapy designation and inclusion in its START Pilot Program. Baird sees the next catalyst for Neurogene shares as data at the IRSF Scientific Meeting on competitor TSHA-102, in development by Taysha Gene Therapies (TSHA).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene’s NGN-401 Therapy Advances under FDA START Program
- FDA accepts Neurogene’s NGN-401 gene therapy for Rett into START Pilot program
- Taysha Gene Therapies assumed at Buy from Hold at Jefferies
- Neurogene price target lowered to $51 from $55 at H.C. Wainwright
- Neurogene Inc. Optimistic on NGN-401 Trial Progress